X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES TORRENT PHARMA ALKEM LABORATORIES/
TORRENT PHARMA
 
P/E (TTM) x - 27.2 - View Chart
P/BV x 7.4 5.2 143.2% View Chart
Dividend Yield % 0.6 1.1 55.6%  

Financials

 ALKEM LABORATORIES   TORRENT PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
TORRENT PHARMA
Mar-17
ALKEM LABORATORIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,768 89.9%   
Low Rs1,2321,186 103.9%   
Sales per share (Unadj.) Rs417.5346.1 120.6%  
Earnings per share (Unadj.) Rs56.355.2 102.0%  
Cash flow per share (Unadj.) Rs64.773.3 88.3%  
Dividends per share (Unadj.) Rs12.7014.00 90.7%  
Dividend yield (eoy) %0.90.9 95.0%  
Book value per share (Unadj.) Rs292.9257.1 114.0%  
Shares outstanding (eoy) m119.57169.22 70.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.3 79.2%   
Avg P/E ratio x25.126.8 93.6%  
P/CF ratio (eoy) x21.820.1 108.2%  
Price / Book Value ratio x4.85.7 83.8%  
Dividend payout %22.625.4 88.9%   
Avg Mkt Cap Rs m168,653249,887 67.5%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m9,1719,934 92.3%   
Avg. sales/employee Rs ThNM4,971.5-  
Avg. wages/employee Rs ThNM843.2-  
Avg. net profit/employee Rs ThNM792.4-  
INCOME DATA
Net Sales Rs m49,91558,569 85.2%  
Other income Rs m1,6452,233 73.7%   
Total revenues Rs m51,56160,802 84.8%   
Gross profit Rs m8,48213,773 61.6%  
Depreciation Rs m1,0063,069 32.8%   
Interest Rs m6712,056 32.6%   
Profit before tax Rs m8,45110,881 77.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,545 103.9%   
Profit after tax Rs m6,7319,336 72.1%  
Gross profit margin %17.023.5 72.3%  
Effective tax rate %19.014.2 133.8%   
Net profit margin %13.515.9 84.6%  
BALANCE SHEET DATA
Current assets Rs m27,06253,841 50.3%   
Current liabilities Rs m15,32431,612 48.5%   
Net working cap to sales %23.538.0 62.0%  
Current ratio x1.81.7 103.7%  
Inventory Days Days6797 68.4%  
Debtors Days Days4184 49.3%  
Net fixed assets Rs m12,61042,079 30.0%   
Share capital Rs m239846 28.3%   
"Free" reserves Rs m34,49042,655 80.9%   
Net worth Rs m35,02743,501 80.5%   
Long term debt Rs m1,21222,408 5.4%   
Total assets Rs m54,387101,250 53.7%  
Interest coverage x13.66.3 216.1%   
Debt to equity ratio x00.5 6.7%  
Sales to assets ratio x0.90.6 158.7%   
Return on assets %13.611.3 121.0%  
Return on equity %19.221.5 89.5%  
Return on capital %24.919.6 126.6%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56320,066 32.7%   
Fx outflow Rs m3,0125,304 56.8%   
Net fx Rs m3,55214,762 24.1%   
CASH FLOW
From Operations Rs m7,25910,127 71.7%  
From Investments Rs m1,864-7,869 -23.7%  
From Financial Activity Rs m-9,273-1,918 483.5%  
Net Cashflow Rs m-150212 -70.9%  

Share Holding

Indian Promoters % 66.9 71.5 93.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 7.0 471.5%  
FIIs % 0.0 12.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.8 -  
Shareholders   68,381 26,511 257.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - ELDER PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS